On the HCPLive news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.
New Biomarkers Predict Adverse Events in Cardiac Sarcoidosis
March 23rd 2023Data from a meta-analysis show late gadolinium enhancement (LGE) on cardiac MRI scans and elevated fluorodeoxyglucose (FDG) uptake on PET scans are both strong predictors of major adverse cardiac events for cardiac sarcoidosis.
Failure to Reach LDL-C Target Increases Event Risk Nearly 50% in High-Risk Individuals
March 23rd 2023New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.
CRAVE Trials Offers Most Comprehensive Overview Yet of Impact of Coffee, Caffeine Intake
March 23rd 2023A 14-day randomized clinical trial assessing effects of caffeinated coffee consumption in a population of 100 adult patients, CRAVE offers what could be the most definitive insight yet into the effects of coffee consumption on overall health.
Statin Use for ASCVD Prevention Lower Among Black, Hispanic Individuals
March 22nd 2023An analysis of NHANES from 2013 - March 2020 suggest individuals with an indication for statin therapy for primary prevention based on 10-year risk saw low overall use across risk categories and race and ethnicity strata.
AHA/ACC Scientific Statement Reports Benefit of Supervised Exercise Training for HFpEF
March 22nd 2023Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.
FDA Approves Evinacumab for HoFH in Children Aged 5-11 Years Old
March 22nd 2023The US FDA has approved an indication for evinacumab for use as an adjunct to other lipid-lowering therapies in children with homozygous familial hypercholesterolemia as young as 5 years old, which makes evinacumab the first ANGPTL3 inhibitor indicted for this patient population.
Adalimumab Biosimilar for Uveitis Similarly Efficacious to Bio-Originator
March 22nd 2023Data from the United Kingdom indicate Amgevita is safe and effective for non-infectious uveitis with non-inferiority to originator adalimumab, but a significant number of patients requested to switch back due to adverse events.
Improving Built Environments Could Help Address Adolescent Obesity
March 21st 2023Built environments, but not social and economic environments, were negatively associated with BMI and overweight or obesity status, with a stronger association among adolescents with longer exposure to their built environment.